Chondrosarcoma radiotherapy with helical delivery and analysis of MR guidance by Namita Sabbarwal et al.
 
Asian Pac. J. Health Sci., 2018; 5(3):292-299                                      e-ISSN: 2349-0659,   p-ISSN: 2350-0964                    
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________  
Aggarwal  et al                    ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2018; 5(3):292-299                                         292 
www.apjhs.com                                      
 
 
Document heading    doi: 10.21276/apjhs.2018.5.3.42                                                                                        Research Article 
Chondrosarcoma radiotherapy with helical delivery and analysis of MR guidance 
 
Suresh Aggarwal
1*
, Naveen Singh
1
, Namita Sabbarwal
2 
 
1
Department of Oncology,Government Hospital,Hisar, Haryana,India 
2
Division of Biophysics, Department of Physics,Government College,Adampur, Hisar, Haryana,India 
 
Received: 15-08-2018 / Revised: 20-09-2018 / Accepted: 29-09-2018 
 
ABSTRACT 
 
Purpose: To screen cell and metabolic qualities of chondrosarcoma of thoracic spine through the span of standard 6-
week chemoradiation treatment on helical delivery with compound trade immersion exchange - MRI; and to 
recognize the most suitable process for CEST could decide consequent restorative reaction. Material and Methods: 
Twelve patients with recently analyzed chondrosarcoma were selected, and CEST-MRI was obtained promptly 
previously (Day0), 2 weeks (Day14) and a month (Day28) into treatment, and multi month after the finish of 
treatment (Day70). A few CEST measurements, including charge exchange proportion and region under the bend of 
CEST tops relating to atomic Overhauser impact  and amide protons (MTRNOE, MTRAmide, CESTNOE, and 
CEST Amide separately), polarization exchange (MT), and direct water impact were examined. Normal tissue 
volume with target volume coverage was analyzed with plans yielding mean low dose. Absence of early movement 
was resolved as no expansion in tumor size or intensifying of clinical side effects as per routine post-chemoradiation 
serial auxiliary MRI. Results : Changes in MTRNOE (nonprogressors = 1.35 ± 0.18, progressors = 0.97 ± 0.22, P = 
.006) and MTRAmide (nonprogressors = 1.25 ± 0.17, progressors = 0.99 ± 0.10, P = .017) between pattern (Day0) 
and Day14 brought about the best detachment of nonprogressors from progressors. Besides, the pattern (Day0) 
MTRNOE (nonprogressors = 6.5% ± 1.6%, progressors = 9.1% ± 2.1%, P = .015), MTRAmide (nonprogressors = 
6.7% ± 1.7%, progressors = 8.9% ± 1.9%, P = .028), MT (nonprogressors = 3.8% ± 0.9%, progressors = 5.4% ± 
1.4%, P = .019), and CESTNOE (nonprogressors = 4.1%ċHz ± 1.7%ċHz, progressors = 6.1%ċHz ± 1.9%ċHz, P = 
.044) could distinguish progressors even before the beginning of the treatment.  
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Introduction 
Magnetic resonance imaging (MRI) is rarely used in 
assessing response of chondrosarcoma to therapy. 
Current response evaluation criteria [1]rely on 
structural changes in tumor size, which take months to 
occur. Considering the poor prognosis of 
chondrosarcoma patients [2], a biomarker of response 
that could identify progressive tumor early after 
completion of, during, or even before treatment 
(through characterizing tumor aggressiveness) could 
have significant clinical utility. 
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Several functional MRI biomarkers, such as magnetic 
resonance spectroscopy, magnetization transfer (MT), 
diffusion-weighted MRI, and dynamic contrast-
enhanced MRI, have been investigated in assessing 
chondrosarcoma response at 1 to 3 months after 
therapy [3]. This post chemoradiation time point is the 
accepted standard for response evaluation in clinical 
practice. However, very few studies have explored the 
potential for advanced MRI-based biomarkers during 
the course of chemoradiation in humans [4]. As 
chondrosarcoma treatment advances into the era of 
daily MRI-guided radiation therapy [5], the ability to 
perform daily imaging of tumors and exploring the 
potential to perform true adaptive radiation therapy and 
biologic response-based planning is imminent. A 
massive coordinated effort to standardize and explore 
novel sequences that are non–contrast-based is urgently 
in need. This study explores the potential for chemical 
exchange saturation transfer (CEST) imaging to be a 
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novel non–contrast-based imaging biomarker able to 
monitor and quantify metabolic changes secondary to 
treatment effects. 
Chemical exchange saturation transfer is sensitive to 
concentration and exchange of labile protons in the 
tissue [6]. Ample research in cancer CEST has shown 
that concentration of certain labile protons changes in 
tumors. The exchange rate of these protons with water 
protons, which is sensitive to many micro-
environmental factors, such as pH, also changes in 
tumors. Numerous CEST metrics, including amide 
proton transfer (APT), have been used in tumor 
characterization and evaluating chondrosarcoma 
response to therapy. Zaiss et al showed that tumors 
have significantly lower CEST signal at the frequency 
offset corresponding to nuclear overhauser effect 
(NOE). Sagiyama et al showed, in a rat model of 
chondrosarcoma, that CEST was capable of predicting 
response to temozolomide within 1 week. Ma 
et al successfully differentiated pseudo-progression 
from true progression in chondrosarcoma using APT 
3 months after the treatment. McVicar et al 
[7] demonstrated the ability of APT in determining 
response to chemotherapy (tumor acidification with 
lonidamine) in a chondrosarcoma model in mice as 
early as 1 hour after treatment. Scheidegger 
et al compared the CEST signal of chondrosarcoma 
and normal white matter and concluded that the main 
contributor to their differences was the MT contrast. 
The delivery with helical tomotherapy for IMRT is 
well established in cases requiring durable local control 
with high doses[8]. As per literature the spinal cord 
tolerance dose of 45 to 55 Gy is quite below the 
radiation dose required for chondrosarcoma and helical 
intensity modulated delivery with tomotherapy is 
reported to be effective in achieving the prescribed 
dose with available clinical limitations. The study 
further reported that sensitive tumor target volume and 
sensitive normal tissue sparing should be monitored[8]. 
Chemical exchange saturation transfer is sensitive to 
treatment-induced changes, such as apoptosis due to 
radiation therapy [9]or pH normalization caused by 
temozolomide [10]. These changes occur much earlier 
than morphologic changes in tumor dimensions and 
make CEST a promising candidate for early response 
evaluation. The present study investigates monitoring 
CEST in chondrosarcoma over the course of a standard 
6-week chemoradiation treatment to determine the 
earliest time point therapeutic response could be 
evaluated. Assessing response before or within early 
phases of the treatment may allow for tailoring of the 
treatment plan to the individual patient's tumor biology 
and may improve outcome. Recently, researchers at 
University of Wisconsin, successfully completed the 
consistency measurements for delineated field strength 
and baseline procedure measurements with their scan 
protocol and ultimately monitored the MRI scanner 
using MR guided RT planning. This approach 
motivates us to encapsulate MR simulations in the 
treatment delivery process [11] 
 
Materials and Methods 
 
Twelve patients with newly diagnosed chondrosarcoma 
tumor were recruited (13 male, median age 55 years). 
The study was conducted in accordance with 
regulations and guidelines of the institutional research 
ethics board at Sunnybrook Research Institute. 
Informed consent was obtained from all patients, and 
all experimental protocols were approved by the 
research ethics board.  
Computed Tomography scans of the chest, abdomen, 
and pelvis were used to determine cases of 
metastasis[8]. CT simulated outcomes were exported to 
pinnacle treatment planning system and as per existing 
literature, clinical target volume, regions of interest, 
spinal cord, cord center, esophagus, heart and both 
lungs were contoured [8]. A 5mm expansion was added 
to clinical target volume for selecting planning target 
volume. All patients were treated with intensity 
modulated radiation therapy (≤2 Gy/day with a boost 
of < 20Gy to PTV2[8]. Helical treatment delivery plans 
were generated using a 2.5 cm field width and 0.286 
pitch with normal dose calculations grid of 0.309 x 
0.309 cm
2
[8]. Comprehensive longitudinal MR images 
were acquired at 4 different time points during and 
after the course of treatment, as follows: (1) 
immediately before the start of the treatment (Day0); 
(2) after receiving 10 treatment sessions (Day14); (3) 
after receiving 20 treatment sessions (Day28); and (4) 
4 weeks after the end of the treatment (Day70). 
Response to treatment was determined at longer than 
3 months after the end of the 6-week chemoradiation 
(between 3 and 8 months after treatment, during which 
2 patients were deceased) and was defined as per 
Response Assessment in Neuro-Oncology criteria 
(2) through assessing tumor size (ie, stable tumor) on 
anatomic post-gadolinium (Gd) T1-weighted (T1w) and 
T2-wieighted (T2w) fluid-attenuated inversion recovery 
(FLAIR) MR images, as well as clinical symptoms of 
the patient. Response Assessment in Neuro-Oncology 
criteria were used because they are specifically 
designed to address the issue of pseudo-progression by 
imposing strict rules on determination of progression 
within the first 12 weeks of treatment. Response was 
determined by a senior neuro-oncologist who was 
blinded to the MRI analysis, whereby patients were 
classified as early progressors and nonprogressors 
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MRI acquisition 
The patients were scanned on a 3T Philips Achieva 
MRI system with 8-channel SENSE head coil with the 
following MRI sequences: 3-dimensional (3D) T2w-
FLAIR data (repetition time [TR]/echo time 
[TE]/inversion time 
[TI] = 9000/2800/125 milliseconds, slice 
thickness = 5 mm, 25 slices, field of view 
[FOV] = 24 cm × 24 cm) was used to identify an 
oblique axial slice passing through the largest cross-
section of the tumor for CEST imaging. To ensure 
accurate reproducibility of the CEST slice prescription 
between multiple scans, specific brain structures were 
first used to prescribe the 3D-FLAIR sequence. Then 
the coordinates of the FLAIR slice that passed through 
the largest cross-section of the tumor was used as the 
CEST imaging slice. For subsequent scans, the FLAIR 
scan was prescribed using the same brain structures, so 
that the 3D-FLAIR coverage would be identical to the 
earlier scans of the patient. Then the same FLAIR slice 
number that was used in previous scans was used to 
prescribe the CEST slice. 
Offset frequencies between −750 Hz (−5.9 ppm) to 
750 Hz (5.9 ppm) with increments of 25 Hz were used 
in CEST spectrum data acquisition. Four reference 
images at 100 kHz (approximately 780 ppm) were 
acquired at the beginning, and another 4 reference 
images were acquired at the end of the CEST spectrum 
data acquisition. These reference images were used for 
drift correction and CEST spectrum data normalization 
(12). Chemical exchange saturation transfer data were 
acquired with radio frequency (RF) power 
amplitude, B1 = 0.522 μT, and saturation 
duration, Tsat = 970 milliseconds. The RF saturation 
consisted of 4 block-shaped pulses of 
242.5 milliseconds each. There was also a delay of 
2.5 milliseconds after each block, during which 
spoilers were applied in the slice selection direction. 
The CEST imaging readout was fast field echo (FFE) 
with multi-shot turbo field echo (TFE) factor = 20, 
TR/TE = 7.78/4.5 milliseconds, half scan = 0.8, 
acquisition matrix = 132 × 95, reconstruction 
matrix = 144 × 144, FOV = 20 cm × 20 cm, slice 
thickness = 3 mm. There was also a spectral 
presaturation with inversion recovery (SPIR) fat 
suppression (12 milliseconds) after the saturation 
pulses and before the TFE acquisition. To allow for the 
magnetization to recover and also to satisfy duty cycle 
constraints, a delay was included after TFE acquisition, 
making the time between consecutive saturations equal 
to 2 seconds. Chemical exchange saturation transfer 
imaging was performed twice, for a total duration of 
4.6 minutes. 
T2-mapping was performed on the same slice using 
a T2-weighted spin echo sequence with 10 echo times 
(TE = n × 20 milliseconds, n = 1, 2, 10), 
TR = 3000 milliseconds, FOV = 20 cm × 20 cm, slice 
thickness = 3 mm, matrix size = 80 × 80, α = 90°. T2-
mapping was performed by fitting a mono-exponential 
function to the data on a voxel-by-voxel basis. 
To optimize the process we used the proven approach 
of measurements with several number of OC inserts, 
and considerations of signal to noise ratio alongwith 
uniformity and setup of laser alignment (11). For 
benchmarking we used MRgRT quality control criteria 
from existing work on edge spread transition width 
ranging from 10-90% and signal uniformity restricted 
within 30 cm of diameter (11).  
The Method of Slopes was used for B1- and T1-
mapping (13). Method of Slopes image acquisition 
consisted of high spatial resolution images with small 
flip angles (FFE, α = 3°, 14°, 
TR/TE = 10.7/5 milliseconds, FOV = 20 cm × 20 cm, 
matrix size = 224 × 224 × 40, slice thickness = 2 mm), 
as well as low spatial resolution images with large flip 
angles (FFE, α = 130°, 150°, 
TR/TE = 50/5 milliseconds, FOV = 20 cm × 20 cm, 
matrix size = 80 × 80 × 20, slice thickness = 6 mm). 
The low-resolution, high flip angle images were used 
for B1-mapping, and the high-resolution, low flip angle 
data allowed for high resolution T1-mapping [14] 
CEST analysis 
The CEST images, the multi-echo images for T2-
mapping, and the FFE images for T1/B1-mapping were 
all co-registered to the first acquired CEST image (first 
reference image of the first CEST spectrum) using 
affine registration in Elastix (15). Chemical exchange 
saturation transfer data of each spectrum were first 
normalized to the reference images acquired at the 
beginning of the spectrum. Drift correction was 
performed using the reference images at the 2 ends of 
the CEST spectrum. B0 inhomogeneity correction was 
performed by fitting a Lorentzian line-shape to the data 
surrounding the water resonance (  < 1.3 ppm) 
and the end tails of each spectrum (  > 4.5 ppm). 
The spectrum was then shifted to place the minimum 
on the 0-Hz offset frequency. Any voxel that failed to 
fit to the Lorentzian line-shape was discarded. Data 
were then resampled at the offset frequencies of the 
imaging protocol. The normalized, drift, and B0-
corrected spectrums of the 2 CEST repetitions of each 
voxel were then averaged to generate the final CEST 
spectrum used in calculating the following CEST 
metrics. 
(1) Magnetization transfer ratio (MTR) of amide 
protons, defined as: 
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where S(ref) represented the reference image (equal to 
1 for the normalized CEST spectrum), and 
represented the CEST spectrum value at offset 
frequency  (which was 3.5 ppm for amide protons). 
(2) The MTR of nuclear overhauser effect (NOE) at 
−3.5 ppm: 
 
(3) The conventional amide proton transfer (APT) was 
defined as: 
 
The signal in CEST spectrum represents a combination 
CEST effect, MT, and direct water saturation effect 
(direct effect).  
Tumor ROI 
The tumor ROI was defined on post-Gd T1w data and 
was transferred to the CEST images. To achieve this, 
the 3D volume imaged in post-Gd T1w data was first 
co-registered to the 3D FLAIR data using affine 
registration in Elastix (18). It was then interpolated 
with the voxel resolution of the CEST data, and the 
oblique axial slice corresponding to CEST was selected 
(CEST slice matched a slice of the 3D FLAIR data). 
Two analysis ROIs were then defined and were used in 
longitudinal evaluation of the CEST metrics: (1) ROI 
type I: the tumor ROI was defined as the enhancing 
region on the post-Gd T1w slice that was acquired at 
each scan; (2) ROI type II: The tumor ROI was defined 
as the enhancing region on the post-Gd T1w slice at the 
baseline scan and was kept constant for the subsequent 
scans. 
In ROI type I, the CEST metrics represented the 
average CEST properties of the tumor ROI, and thus 
change in the tumor size was not taken into account. In 
ROI type II, however, the ROI was defined at the first 
scan, and if the tumor size changed over time, other 
tissues (eg, peritumoral tissue) would enter the ROI, 
thus change in tumor size would affect the average 
CEST metric value in ROI type II. The ROI type II 
represented the brain region that received the highest 
radiation dose (defined in radiation therapy planning 
stage) throughout the treatment. By investigating both 
ROI types, a more comprehensive understanding of the 
CEST metric changes over the course of the treatment 
was achieved.  
Normal tissue 
The CEST metrics were also calculated on an ROI of 
cNAWM. This measurement was performed to monitor 
the reproducibility of the CEST metrics between 
patients and also over the course of the treatment 
(intersubject and intrasubject reproducibility). The 
cNAWM ROI was defined on an area of uniform signal 
intensity in the white matter in post-Gd-T1w MRI. 
Considering the invasive nature of chondrosarcoma 
cells and the fact that they could migrate far from the 
tumor (even to the contralateral hemisphere of the 
brain) (19), the cNAWM was chosen to be on the 
farthest possible (from tumor) white matter region on 
the contralateral hemisphere. 
 
Results 
 
Data of 3 patients were discarded because of 
significant motion and imaging artifacts in the tumor 
ROI. The remaining 16 patients were classified by the 
blinded neuro-oncologist into nonprogressors (10 
patients) and progressors (6 patients) at the time of last 
follow-up. A few of the patients did not complete all 4 
scans and therefore there were the following number of 
patients at each time point: Day0: 10 nonprogressors, 6 
progressors; Day14: 10 nonprogressors, 4 progressors; 
Day28: 8 nonprogressors, 3 progressors; Day70: 10 
nonprogressors, 3 progressors. 
For each patient, the CEST metrics were calculated 
voxel by voxel, and then the average metric value over 
the tumor and cNAWM ROIs was calculated and used 
in subsequent statistical analyses. 
To minimize operator bias in selecting tumor and 
cNAWM boundaries, the ROIs were defined on the 
post-Gd T1wMRI and then transferred to the CEST slice 
(by co-registering the 2 datasets). The reproducibility 
of the CEST metrics was examined on the cNAWM 
(reported in Table E-1; available online 
at www.redjournal.org). For cNAWM, no statistically 
significant difference was observed between the CEST 
metrics of any 2 time points (assessed by Wilcoxon 
rank-sum test) or between progressors and 
nonprogressors (assessed by unpaired ttest), 
demonstrating the stability and reproducibility of the 
experiments. 
The MTRNOE and MTRAmide maps show lower MTR 
values on the tumor compared with normal tissue and 
regions of edema. These lower MTR values are mainly 
due to the low MT effect of the tumor compared with 
normal tissue. Similarly, CESTNOE is showing lower 
values for the tumor; however, CESTAmide in the tumor 
is showing values that are higher than normal tissue 
(which is expected for the tumor). 
The mean and standard deviation of the CEST metrics 
(segregated into progressors and nonprogressors) are 
reported for the ROI type I, in which tumor ROI was 
defined as enhancing region on the post-Gd T1w image 
at each time point. The parameter pairs that were 
statistically significantly different between progressors 
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and nonprogressors are noted with a dagger symbol (†). 
When focusing on the absolute value of the metrics for 
tumor ROI only (ROI type I), the MTRNOE (P = .015), 
MTRAmide (P = .028), MT (P = .019), and 
CESTNOE (P = .044) at baseline (Day0) were 
statistically significantly different between the 
progressors and nonprogressors. However, none of the 
metrics at any subsequent time point were able to 
differentiate the 2 cohorts. These CEST metrics show 
that nonprogressors are less metabolically active 
compared with progressors before treatment. 
The distribution (mean and standard deviation) of 
CEST metrics for ROI type II is reported, in which 
tumor ROI was defined at Day0 scan and was kept the 
same for consecutive time points and thus takes the 
changes in tumor size into account as well. Similar to 
ROI type I, the absolute value of the metrics at Day14, 
Day28, and Day70 were unable to differentiate 
progressors from nonprogressors. This data 
demonstrates that there is significant difference in 
CEST metrics of the 2 cohorts before treatment and 
that they become similar as treatment is administered. 
Similar separations were observed when using ROI 
type II. The ratios (Day14 over Day0) of 
MTRNOE(nonprogressors = 1.30 ± 0.19, 
progressors = 0.93 ± 0.31, P = .02) and 
MTRAmide (nonprogressors = 1.20 ± 0.20, 
progressors = 0.92 ± 0.27, P = .05) differentiated the 2 
cohorts. This data demonstrates that there is no 
significant change in the direct effect at any time point, 
showing that treatment is not changing T1 or T2 values 
of the tumor. The MT metric did not change for 
progressors; however, in nonprogressors there was an 
increase in this metric as early as 2 weeks into the 
treatment, which stayed relatively unchanged (slightly 
decreased) at the last 2 scans. The CEST signals also 
stayed unchanged for progressors, showing that 
treatment was not inducing any metabolic changes in 
the tumor. However, for nonprogressors the increase in 
CEST metrics could be due to inflammatory response 
to the tumor cells being destroyed by the treatment; it 
could also stem from pH normalization by 
temozolomide. 
The ratios of CEST metric values at Day28 or 
Day70 over baseline did not provide a statistically 
significant separation of the 2 cohorts. This could 
potentially be associated with having very few 
progressors participating in the later follow-up scans. 
In the present longitudinal evaluation of human 
chondrosarcoma response to therapy, CEST data of 
patients at multiple time points was obtained before, 
during, and after the end of the 6-week standard 
chemoradiation treatment. The objectives were to (1) 
investigate the potential of CEST in evaluating 
chondrosarcoma response to treatment; (2) determine 
the earliest time point at which CEST could identify 
nonprogressors; and (3) identify the CEST metrics (if 
any) that were able to characterize tumor 
aggressiveness before the treatment. 
The CEST metrics were first calculated on the 
cNAWM region of each patient. As reported in Table 
E1 (available online at www.redjournal.org), there was 
no statistically significant difference between the 
CEST metrics on cNAWM between consecutive time 
points, and there was a small variation in the metric 
values. These results show there was no intersubject or 
intrasubject variability, which demonstrates 
reproducibility of the experiments and that the 
differences in measured metrics represent the 
differences between tumors and are not due to 
experimental conditions [16] 
The main goal of radiotherapy delivery for normal 
tissue dosimetry in controlled target volume treatment 
plans met the criteria set by Yadav et al (8). Left lung 
dose parameters of dose within 68,12,80,10,1.5 (Dmax, 
Dmean,V5, V20, V40), right lung dose within 18, 14, 
81, 15, 4 Gy (Dmax, Dmean, V5, V20, V40), heart 
dose parameters  within 40, 15, 4 (Dmax, Dmean, 
V25), Esophagus dose parameters with values within 
60, 20, 41 (Dmax, Dmean, V20), cord center Dmax < 
43 and Dmean < 18 Gy and spinal cord Dmax < 56 Gy 
and Dmean less the 11 Gy were met (8). These dose 
constraints helped in establishing the fact that not only 
modality specific but universal planning constraints 
were met (including IMRT, Dynamic arc, Tomo, and 
proton therapy) [8] 
The CEST spectrum signal reflects the combination of 
several effects: direct effect (representing the 
longitudinal and transverse relaxation times), MT 
effect (representing the macromolecular content), and 
CEST effects (generated from labile proteins and 
peptides). The MTR metrics reported here represent the 
combination of all 3 components (CEST, MT, and 
direct effect), the MT metric (derived from Lorentzian 
decomposition) represents the combination of direct 
effect and the MT effect, and the CEST metrics 
represent the actual isolated CEST effects. 
To probe the changes in CEST metrics over the course 
of the treatment, 2 different ROIs were defined to 
provide a comprehensive assessment of the CEST 
changes. Region of interest type I focused on the tumor 
tissue only and reflected the evolution (over time) of 
CEST metrics inside the enhancing tumor rim. Because 
radiation treatment planning is performed on the 
pretreatment tumor margins (gross tumor volume as 
per the surgical cavity and any residual disease), the 
analysis region in ROI type II was defined at the 
baseline scan and was kept fixed for consequent scans. 
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This ROI received the highest radiation dose in all of 
the 30 radiation treatment sessions. It also takes into 
account the tumor size change and white matter 
infiltration into the initial tumor area over the course of 
the treatment. The ratio of each metric over its baseline 
value was used to represent the treatment-induced 
changes in the tumor. 
The baseline (Day0) values of the MTRNOE (P = .015), 
MTRAmide (P = .028), MT (P = .019), and 
CESTNOE (P = .044) were capable of differentiating 
progressors from nonprogressors. All the CEST metrics 
reported for Day0 of nonprogressors were lower 
(except for APT), showing they had lower metabolic 
activity compared with progressors (although direct 
effect and CESTAmide and APT were not statistically 
significantly different). Thus, CEST is capable of 
characterizing chondrosarcoma tumor aggressiveness 
and identifying patients who will not benefit from 
standard chemoradiotherapy, even before the start of 
the treatment. Furthermore, although there were large 
differences in the CEST metrics at baseline, once the 
treatment was administered there were no statistically 
significant differences (at subsequent time points) 
between the 2 cohorts. 
When considering the changes in metrics during 
treatment, there was statistically significant difference 
(for ROI type I) between progressors and 
nonprogressors for MTRNOE (P = .006) and 
MTRAmide (P = .017) of changes between Day0 and 
Day14. Similar separation (with higher P values) of the 
progressors and nonprogressors was also achieved for 
changes between Day0 and Day14 in ROI type II (for 
MTRNOE and MTRAmide with P = .02 and P = .05, 
respectively). However, the changes in metrics for the 
later time points (Day28 and Day70) were not 
statistically significant different between the 2 cohorts. 
Nevertheless, considering the ratios and ratio 
trends(which show the ratios did not change from 
Day14 to later scans), the lack of statistical significance 
in these later time points could be associated with the 
fact that very few progressors participated in these 
scans. 
There were large variations in CESTNOE metric in all 
groups and at all scan time points. This metric was 
calculated from Lorentzian decomposition of the CEST 
spectrum. The NOE is a wide peak that ranges between 
−2 ppm and −5 ppm [17]and encompasses a variety of 
effects, thus larger variations were observed in its AUC 
as a result of the treatment. 
The CESTAmide signal in nonprogressors was elevated 
at Day14, but it decreased over time, whereas for 
progressors this metric slightly increased at Day14 and 
continued to increase over the course of the study. 
CESTAmide (similar to APT) is expected to quantify the 
concentration and exchange of amide proton in the 
tumor, which has been shown to increase with the 
aggressiveness of the tumor (17). However, the 
difficulties in accurately measuring this metric (due to 
having a narrow CEST peak) resulted in large 
variations in its value, which led to CESTAmide not 
being able to separate the 2 cohorts of patients. 
The CEST signal patterns explain the higher APT 
values in the tumor region, which might be due to 
higher cellularity of the tumor (as shown by Bai et al 
(34)). On the other hand, the co-localization of the high 
APT values with the high T1 values and absence of 
high APT values in portions of the tumor that had 
lower T1 values might suggest that these patterns were 
due to the differences in the T1 and, if T1 differences 
were eliminated, the high APT value regions might 
disappear (as demonstrated by Zaiss et al). These 
points highlight the issues and difficulties in accurately 
isolating the APT signal particularly in the low-power 
saturation approaches that were used in this study. 
Lorentzian decomposition is an alternative approach 
for measuring the CEST signal of amide protons; 
however it yielded very noisy CESTAmide map, mainly 
owing to its narrow and low amplitude CEST peak. 
Tumor volume was not capable of separating the 2 
cohorts at any of the scan time points which shows a 
longer follow-up was needed for such differentiation 
using clinically used metrics. The presented CEST 
results showed that the best and earliest time point for 
evaluating chondrosarcoma response to treatment was 
2 weeks into the treatment (Day14), and the best CEST 
metrics were the changes in MTR metrics between 
Day14and baseline. Additionally, the largest treatment-
induced changes in the CEST properties occurred 
during the first 2 weeks of the treatment, demonstrating 
the higher sensitivity of CEST to treatment effects. It is 
important to note that the CEST metrics at later time 
points were not able to differentiate the 2 cohorts, or 
provided weaker separation. Thus, the CEST metrics at 
early phases of the therapy are the most sensitive to 
treatment effects. 
In case of the progressors (who had more aggressive 
and highly metabolically active tumors) the metric 
values over time were relatively unchanged, showing 
that the treatment was unable to induce significant 
changes in the tumor. However, for nonprogressors 
there were significant increases in CEST metrics, 
showing that the therapy was changing tumor 
metabolism (particularly at early phases of the 
treatment). Moreover, the trendsshow that the changes 
in MTR metrics after Day14 mirrored that of the MT 
metric. This point suggests the CEST response 
(attributed to the inflammatory response in the tumor 
and temozolomide-induced pH normalization) was 
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elevated in the nonprogressors and stayed elevated 
throughout the therapy. However, the MT metric 
(governed by the macromolecular content and their 
access to free water) decreased after Day14, which 
could indicate increased cell death over time. 
Results demonstrate that tumors in nonprogressors 
were less metabolically active (compared with 
progressors) and, therefore, had lower CEST metrics at 
Day0. Once the treatment was given, the 
nonprogressors were less resistant to the treatment, and 
thus their CEST metrics changed significantly, whereas 
the progressors were more resistant and the treatment 
could not affect their CEST metric values. These trends 
could be attributed to the combination of 2 main 
factors. (1) There was higher treatment-induced cell 
death in nonprogressors, which induces inflammation 
and higher pH normalization induced by 
temozolomide, which increases CEST signal[2].It has 
been demonstrated that the amount of MT increases 
with response to treatment (the MT component 
measured with Lorentzian decomposition was also 
showing this change semi-quantitatively), because MT 
is a major component of the MTR metrics (MTRNOE, 
MTRAmide), increase in MT (which is mainly governed 
by the macromolecular content and their access to free 
water) is also contributing to the increase in MTR 
metrics.The main limitation of this pilot study was its 
small sample size. Although the differences between 
CEST metrics of the 2 cohorts were large, there were 
only 6 patients with progressive tumors at baseline and 
only 4 participated in the follow-up scans. A larger 
number of progressors are needed to increase 
confidence in the results and establish CEST as a 
biomarker of chondrosarcoma response to treatment. 
This pilot study, however, demonstrated the potential 
of CEST in chondrosarcoma response evaluation and 
also allowed for determination of the best CEST 
metrics and the earliest time point CEST could 
determine chondrosarcoma response to 
chemoradiation. A subsequent larger study is in 
progress to confirm these results. 
Moreover, CEST sequences are not currently available 
on clinical scanners, and their application is limited to 
the research centers with access to the CEST imaging 
sequence. However, all major MRI manufacturers 
(Philips, Siemens, GE) are currently working toward 
making CEST sequences available as standard 
sequence on their scanners (they all have work in 
progress sequences at the moment), which will make 
widespread application of CEST imaging feasible in 
the near future. 
Another major challenge is the long scan time and the 
fact that a single slice through the tumor was 
investigated. The imaging slice was selected such that 
it covered the largest cross section of the tumor, 
covering 1.1 (cm
3
) to 5.9 (cm
3
) of the total tumor 
volume, which represented 8% to 21% of the total 
tumor volume of the patients. Advanced 3D CEST 
sequences with full brain coverage as well as their 
addition to the product sequences offered by MRI 
scanner manufacturers are needed for translation of 
these techniques into routine clinical practice. 
This study demonstrated the feasibility of adding CEST 
sequences to the clinical imaging protocol of the 
chondrosarcoma patients in a clinically acceptable scan 
time. A large number of CEST metrics were 
investigated and their potential in determining 
chondrosarcoma response to therapy was evaluated. 
Amongst these metrics, the best performance was 
achieved by the MTR metrics, which reflect the 
combination of treatment-induced changes in CEST, 
MT, and direct effect of the tumor. Future studies could 
focus on a certain portion of the CEST spectrum to 
improve metric measurement accuracy and reduce 
imaging time. From the retrospective analysis of MRI 
planning parameters as per qc phantom reported doses 
can help in improvement in both treatment planning as 
well as treatment delivery and hence can raise the 
utilization of onboard MR scanners[11]Determining 
chondrosarcoma response at early phases of the 
treatment and identifying the patients that will not 
benefit from standard therapy have the potential for 
significant clinical utility in the era of MRI-based 
image-guided radiation therapy. The lack of contrast 
required for advanced MRI technique such as CEST is 
a major advantage because with daily MR imaging the 
patient cannot be administered contrast regularly. The 
present study also showed the best predictive power 
and most profound treatment-induced changes occur 
inside the ROI type I volume as opposed to ROI type II 
volume. This suggests that plan adaptation can be 
tailored to the evolving gross tumor volume. By 
imaging patients daily and before each radiation 
therapy fraction, the changes in CEST metrics could 
potentially be used as a biomarker for dose escalation 
or to guide changes in systemic therapy. 
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